What has FDA cited under 21 CFR 211.194(a)?

1 DSRV article cite 21 CFR 211.194(a). Enforcement cases behind them: Genzyme Ireland FDA Warning Letter, June 22, 2026. Inspection exposure across them: 1 high.

What does DSRV recommend for 21 CFR 211.194(a)?

From the newest article (FDA Is Treating Discarded Evidence as a Quality Unit Failure): Inspection readiness is not having enough records after the fact — it is decision trails strong enough that FDA does not have to guess what the quality unit knew, reviewed, or allowed. DSRV is decision support, not legal advice; verify against the official source each article names.

Browse by regulation1 article · 1 high

21 CFR 211.194(a)

Every DSRV article whose Regulatory Snapshot cites 21 CFR 211.194(a): the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.

Inspection exposure across the set

What has FDA cited under 21 CFR 211.194(a)?: 1 DSRV article cite 21 CFR 211.194(a). Enforcement cases behind them: Genzyme Ireland FDA Warning Letter, June 22, 2026. Inspection exposure across them: 1 high.
What does DSRV recommend for 21 CFR 211.194(a)?: From the newest article (FDA Is Treating Discarded Evidence as a Quality Unit Failure): Inspection readiness is not having enough records after the fact — it is decision trails strong enough that FDA does not have to guess what the quality unit knew, reviewed, or allowed. DSRV is decision support, not legal advice; verify against the official source each article names.

July 20267 min readHigh exposurecited as a tag
FDA Is Treating Discarded Evidence as a Quality Unit Failure
FDA's June 22, 2026 warning letter to Genzyme Ireland shows how undocumented retesting, discarded review artifacts, and canceled deviations now read as quality-unit governance failures. Small pharma quality teams should treat this as a warning that incomplete records are no longer a narrow documentation problem.
Case
Genzyme Ireland FDA Warning Letter, June 22, 2026
DSRV take
Inspection readiness is not having enough records after the fact — it is decision trails strong enough that FDA does not have to guess what the quality unit knew, reviewed, or allowed.

Address this risk

Pressure-test your evidence before an inspector reads it

Bring the document that has to hold up under 21 CFR 211.194(a). DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.

Apply for the Stability Pilot Ask The Vault about 21 CFR 211.194(a)

Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.